281 reports of this reaction
3.2% of all DECITABINE reports
#5 most reported adverse reaction
MYELOSUPPRESSION is the #5 most commonly reported adverse reaction for DECITABINE, manufactured by Accord Healthcare Inc.. There are 281 FDA adverse event reports linking DECITABINE to MYELOSUPPRESSION. This represents approximately 3.2% of all 8,659 adverse event reports for this drug.
Patients taking DECITABINE who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is moderately reported among DECITABINE users, representing a notable but not dominant share of adverse events.
In addition to myelosuppression, the following adverse reactions have been reported for DECITABINE:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 281 FDA reports for DECITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 3.2% of all adverse event reports for DECITABINE, making it a notable side effect.
If you experience myelosuppression while taking DECITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.